» Articles » PMID: 33162889

Fecal Microbial Signatures Are Associated With Engraftment Failure Following Umbilical Cord Blood Transplantation in Pediatric Crohn's Disease Patients With Deficiency

Overview
Journal Front Pharmacol
Date 2020 Nov 9
PMID 33162889
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Umbilical cord blood transplantation (UCBT) is associated with a relatively high rate of engraftment failure. This study aimed at exploring whether any fecal microbiota could be associated with engraftment failure following UCBT in Crohn's disease patients with deficiency.

Methods: Thirteen patients were recruited and their 230 fecal samples were collected longitudinally from immediately before conditioning chemotherapy to 8 weeks post the UCBT. The V3-V4 regions of the bacterial 16S rRNA gene were amplified by PCR and sequenced, followed by bioinformatics analyses.

Results: Following the UCBT, 7 out of 13 patients achieved neutrophil and platelet engraftment with a median of 21 and 28 days, respectively (S group), while 6 patients failed to achieve engraftment (F group). In comparison with that in the S group, significantly lower Shannon diversity values on the UCBT day ( = 0.0176) and less abundance of , , , and one taxon of family was detected in the F group, accompanied by significantly higher abundances of four taxa including , , and species during the chemotherapy period as well as UCBT. The abundances of thirty OTUs were correlated significantly with clinical indices.

Conclusions: Microbial indicators of reduced diversity of microbiota and signatures of specific bacterial abundances, such as a lower abundance of , for engraftment failure would require validation. These indicators may help for the risk stratification in patients with deficiency undergoing UCBT.

Citing Articles

Distinctive circulating microbial metagenomic signatures in the plasma of patients with lung cancer and their potential value as molecular biomarkers.

Chen H, Yao X, Yang C, Zhang Y, Dong H, Zhai J J Transl Med. 2025; 23(1):186.

PMID: 39953591 PMC: 11829562. DOI: 10.1186/s12967-025-06209-8.

References
1.
Ingham A, Kielsen K, Cilieborg M, Lund O, Holmes S, Aarestrup F . Specific gut microbiome members are associated with distinct immune markers in pediatric allogeneic hematopoietic stem cell transplantation. Microbiome. 2019; 7(1):131. PMC: 6744702. DOI: 10.1186/s40168-019-0745-z. View

2.
Huang Z, Peng K, Li X, Zhao R, You J, Cheng X . Mutations in Interleukin-10 Receptor and Clinical Phenotypes in Patients with Very Early Onset Inflammatory Bowel Disease: A Chinese VEO-IBD Collaboration Group Survey. Inflamm Bowel Dis. 2017; 23(4):578-590. DOI: 10.1097/MIB.0000000000001058. View

3.
Kiernan J, Damien P, Monaghan M, Shorr R, McIntyre L, Fergusson D . Clinical Studies of Ex Vivo Expansion to Accelerate Engraftment After Umbilical Cord Blood Transplantation: A Systematic Review. Transfus Med Rev. 2017; 31(3):173-182. DOI: 10.1016/j.tmrv.2016.12.004. View

4.
Taur Y, Jenq R, Ubeda C, van den Brink M, Pamer E . Role of intestinal microbiota in transplantation outcomes. Best Pract Res Clin Haematol. 2015; 28(2-3):155-61. PMC: 4656136. DOI: 10.1016/j.beha.2015.10.013. View

5.
Glocker E, Kotlarz D, Boztug K, Gertz E, Schaffer A, Noyan F . Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009; 361(21):2033-45. PMC: 2787406. DOI: 10.1056/NEJMoa0907206. View